DE69739276D1 - Methoden zur diagnose und prognose von krebs - Google Patents

Methoden zur diagnose und prognose von krebs

Info

Publication number
DE69739276D1
DE69739276D1 DE69739276T DE69739276T DE69739276D1 DE 69739276 D1 DE69739276 D1 DE 69739276D1 DE 69739276 T DE69739276 T DE 69739276T DE 69739276 T DE69739276 T DE 69739276T DE 69739276 D1 DE69739276 D1 DE 69739276D1
Authority
DE
Germany
Prior art keywords
cancer
methods
prb2
mutations
predict
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739276T
Other languages
English (en)
Inventor
Antonio Giordano
Alfonso Baldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GIORDANO, ANTONIO, RADNOR, PA., US
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69739276D1 publication Critical patent/DE69739276D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
DE69739276T 1996-04-05 1997-04-03 Methoden zur diagnose und prognose von krebs Expired - Lifetime DE69739276D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1494396P 1996-04-05 1996-04-05
US1937296P 1996-06-05 1996-06-05
US2019696P 1996-06-21 1996-06-21
US3953297P 1997-03-03 1997-03-03
PCT/US1997/005598 WO1997038125A1 (en) 1996-04-05 1997-04-03 Methods for the diagnosis and prognosis of cancer

Publications (1)

Publication Number Publication Date
DE69739276D1 true DE69739276D1 (de) 2009-04-09

Family

ID=27486431

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739276T Expired - Lifetime DE69739276D1 (de) 1996-04-05 1997-04-03 Methoden zur diagnose und prognose von krebs

Country Status (7)

Country Link
EP (2) EP0906448B1 (de)
JP (2) JP2000510330A (de)
AT (1) ATE423852T1 (de)
AU (1) AU2438997A (de)
CA (1) CA2250854C (de)
DE (1) DE69739276D1 (de)
WO (1) WO1997038125A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19882435B4 (de) * 1997-06-02 2007-09-20 Thomas Jefferson University Verfahren zur Hemmung von Krebszellwachstum mit einem pRb2/p130 exprimierenden Vektor
US7737255B1 (en) * 1998-09-02 2010-06-15 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating various cancers
US6261778B1 (en) * 1998-10-22 2001-07-17 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode SCP proteins, and uses thereof
US20020051990A1 (en) * 2000-06-09 2002-05-02 Eric Ople Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
AU2003274648A1 (en) * 2002-10-22 2004-05-13 Can-Fite Biopharma Ltd. The use of the a3 adenosine receptor as a marker for a diseased state
JP2008535821A (ja) 2005-03-25 2008-09-04 ジェネンテック・インコーポレーテッド 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物
JP2008533991A (ja) * 2005-03-25 2008-08-28 ジェネンテック・インコーポレーテッド 肺癌におけるｃ−ｍｅｔ突然変異

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE120497T1 (de) 1988-05-09 1995-04-15 Univ Temple Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten.
DE69019410T2 (de) * 1989-03-31 1995-10-05 Canji Inc Retinoblastoma-Genprodukt-Antikörper und deren Verwendungen.
US5234811A (en) * 1991-09-27 1993-08-10 The Scripps Research Institute Assay for a new gaucher disease mutation
EP0631584A4 (de) * 1991-02-28 1998-07-01 Dana Farber Cancer Inst Inc Krebs diagnose und therapie.
AU2178292A (en) * 1991-06-03 1993-01-08 Triton Diagnostics, Inc. Epidermal growth factor receptor ectodomain
CA2096497A1 (en) * 1992-05-26 1993-11-27 Patricia Anne Spears Mycobacteria probes
JPH08503367A (ja) * 1992-11-13 1996-04-16 カリフォルニア インスティテュート オブ バイオロジカル リサーチ 遺伝子の挿入及び欠失の検出による新生物の同定
WO1995002328A1 (en) * 1993-07-15 1995-01-26 Indiana University Foundation Mammalian low molecular weight phospholipase a2 nucleotide and amino acid sequences
IL108879A (en) * 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit

Also Published As

Publication number Publication date
AU2438997A (en) 1997-10-29
WO1997038125A1 (en) 1997-10-16
EP0906448A1 (de) 1999-04-07
EP2014772A2 (de) 2009-01-14
JP2000510330A (ja) 2000-08-15
ATE423852T1 (de) 2009-03-15
EP0906448A4 (de) 2004-12-01
EP0906448B1 (de) 2009-02-25
CA2250854A1 (en) 1997-10-16
EP2014772A8 (de) 2009-04-29
CA2250854C (en) 2011-06-21
JP2008283985A (ja) 2008-11-27
EP2014772A3 (de) 2009-05-27

Similar Documents

Publication Publication Date Title
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
Bertario et al. Survival of patients with hereditary colorectal cancer: comparison of HNPCC and colorectal cancer in FAP patients with sporadic colorectal cancer
ATE386938T1 (de) Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
ATE198623T1 (de) Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
JP2013505429A5 (de)
Wongsurawat et al. A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma
DE69739276D1 (de) Methoden zur diagnose und prognose von krebs
ATE317451T1 (de) Verfahren zur diagnose, erkennung, und einstufung von dickdarmkrebs
IL142971A0 (en) S100 proteins and autoantibodies as serum markers for cancer
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
Wollenberg et al. Clinical relevance of circulating tumour cells in the bone marrow of patients with SCCHN
Shoaibi et al. Prostate Specific Antigen‐Growth Curve Model to Predict High‐Risk Prostate Cancer
Brown et al. Use of gene tests to detect hereditary predisposition to cancer: What do we know about cost effectiveness?
WO2003020120A3 (en) Diagnosis and treatment of vascular disease
ATE510025T1 (de) Verfahren für die detektion von mutationen in nukleinsaüren, und die anwendung in der diagnose von genetischen krankheiten und krebs
DE602004013554D1 (de) Verbindungen und verfahren zur diagnose von prostatakrebs
ATE355527T1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
ATE327766T1 (de) Verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gynäkologischer krebserkrankungen
ATE442456T1 (de) Verfahren zur bestimmung von zirkulierender dns in plasma und zum nachweis von krebs
WO2003007801A3 (en) Diagnosis and treatment of vascular disease
US20130267438A1 (en) Use of specific genes for the prognosis of lung cancer and the corresponding prognosis method
ATE474935T1 (de) Verfahren und zusammensetzungen zur bestimmung von mutationen in nukleinsäure und deren verwendung in diagnose von genetischen krankheiten und krebs
ATE329044T1 (de) Gen, das im zusammenhang steht mit gemütskrankheiten

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GIORDANO, ANTONIO, RADNOR, PA., US

8364 No opposition during term of opposition